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Background: In malignant melanoma, it has been published that up to 40% of cancer patients will suffer from
brain metastasis. The prognosis for these patients is poor, with a life expectancy of 4 to 6 months. Calcium
exchange is involved in numerous cell functions. Recently, three types of cellular calcium sequestration have been
reported in the medical literature. The first describes a transgenic mouse model in which an increase of aberrant
calcium channels triggers hypertrophy and apoptosis. The second provides a protective mechanism whereby
astrocytes in the brain inhibit apoptosis of tumor cells by moving ionic calcium out of the tumor cells thru gap
junctions. The third is via calcium chelation, which causes cell apoptosis by converting ionic calcium into a calcium
salt. This process has been shown to operate in atrial myocardial cells, thus not allowing the intracellular calcium
stores to flow through the myocytes intercalated discs. Ideally chemotherapeutic agents would be those that
initiate apoptosis in tumor cells.
Presentation of the Hypothesis: We hypothesize that the recent reported intracellular calcium sequestration by
oxalate chelation, due to its chemical process of converting ionic calcium into a calcium salt, may inhibit the
protective effect of astrocytes on brain tumor metastasized melanoma cells by not allowing free calcium to leave
the metastatic cells, simultaneously apoptosis of tumor and some healthy adjacent cells could occur. This
hypothesis could be extended to include other cancerous tumors such as skin cancers amongst others.
Testing the hypothesis: Using the experimental model showing the protective mechanism of co-cultured reactive
astrocytes and tumor cells treated with oxalates could be used to test this hypothesis in vitro. The calcium specific
von Kossa technique could be used to confirm the presence of chelated intracellular calcium architecture of the
metastatic cells (which is a sign of apoptosis), and extracellular calcium chelation stores of the Astrocytes (which
has been shown to slow neural conduction).
Implications of the Hypothesis: The life expectancy in patients with metastasized malignant melanoma brain
tumors could be significantly prolonged if the chemotherapeutic issue of brain metastasis is overcome. Other
cancerous tumors can also be treated by this Targeted Chelation Approach. Ionic calcium sequestration using
naturally occurring calcium chelators, viz., oxalates, could accomplish this desired outcome.
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Figure 1 Calcium chelated cross section of atrial myocardium
adjacent to ganglionated plexus. Stained via von Kossa technique.
Slide clearly denotes intracellular stained calcium in myocytes and
extracellular chelation of ganglion and nerves. After injection of
100 mM/L of NH4Ox. Arrows (right side of image) showing chelated
cytoplasmic ionic calcium stores of myocytes. Arrows (left side of
image) denote extracellular calcium stores chelation of ganglion and
nerves. Fan Y, Scherlag BJ, Embi A et al. Neural Effects of Oxalic Acid
for Atrial Fibrillation Therapy. 33rd Annual Scientific Session Heart
Rhythm. 2012; 9:S258.
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Ionic calcium increase induces apoptosis in a
transgenic model
At the turn of the century (2001), it was reported that
hypertrophy and apoptosis had occurred in cardiac cells
of a Ca++ dependent transgenic model of cardiac hyper-
trophy. This model manifested an increased number of
L-type calcium channels that provided an increased in-
gress of calcium thereby initiating hypertrophy and
apoptosis [1].Figure 2 Nerve and parasympathetic ganglion of intrinsic cardiac ner
extracellular calcium chelation. Post injection of 100 mM/L of Oxalic Acid.B
neurons and in ganglion/nerve bundle junction. B) Ganglion cell. C) Nerve
for Atrial Fibrillation Therapy. 33rd Annual Scientific Session Heart Rhythm. 20Protective effects of ionic calcium sequestration by
physiologic processes: astrocytes
Cancer chemotherapeutic agents can promote apoptosis
in tumors, attenuating their growth and metastasis.
However, in some cases these chemotherapeutic effects
can be attenuated by physiologic instances of calcium
sequestration. Temporal analyses of melanoma cells
incubated with chemotherapeutic agents have revealed
an increase in cytoplasmic calcium followed by the ap-
pearance of fragmented DNA, one of the hallmarks of
apoptosis [2]. However, activated astrocytes in the brain
seem to protect metastatic melanoma tumor cells from
apoptosis by a form of ionic calcium sequestration. This
has been shown in vitro to be dependent on physical
contact at gap junctions between cultured rat astrocytes
and metastasized melanoma tumor cells that act by re-
ducing the intracellular ionic calcium concentration in
the tumor cell rather than by converting ionic calcium
to calcium carbonate [3].
Effects of ionic calcium sequestration by chelation
Ionic calcium can also be sequestered via chelation to
achieve certain cellular effects. In recent experiments,
we studied the effect of various millimolar per liter
(mM/L) concentrations of oxalates, namely oxalic acid
(OA) and ammonium oxalate (NH4Ox), on the intrinsic
cardiac autonomic nervous system of dogs. An inciden-
tal finding was the infiltration of oxalates into the adja-
cent atrial myocardium resulting in various degrees of
intracellular and extracellular calcium chelation. This
revealed that in the heart, particularly in the intra-neural
connections and at the axon-myocytes junction, calcium
sequestration by oxalate chelation converts the intracel-
lular myocytes’ ionic calcium stores as well as the extra-
cellular ionic calcium of the neural network into calcium
carbonate. This conversion inhibits neural conductionvous system X 40 Magnification. Showing heterogeneous
lack lines denote: A extracellular calcium chelation along edges of
bundle. Fan Y, Scherlag BJ, Embi A et al. Neural Effects of Oxalic Acid
12; 9:S258.
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positive outcome in a patho-physiological situation with
hyperactive neurons in the ganglionated plexi, which
leads to atrial fibrillation [4].
Results from another, ongoing study suggests that
chelation occurs irrespective of the pH of the chelators,
ranging from OA (pH1.6) to NH4Ox (pH 6.7) (Embi A,
Scherlag BJ unpublished observations). The control and
post-injected samples were treated with a specific stain
for calcium via the Von Kossa technique [5]. All control
samples were negative for calcium chelation, on the
other hand all other microinjected samples were positive
for varying degrees of chelation (Figures 1 and 2).
Presentation of the hypothesis
The recent reported intracellular calcium sequestration
by oxalate chelation, due to its chemical process of
converting ionic calcium into a calcium salt, may inhibit
the protective effect of astrocytes on brain tumor metas-
tasized melanoma cells by not allowing free calcium to
leave the metastatic cells. This could be accomplished by
simultaneously apoptosis of malignant cells in the area
targeted. Adjacent non-malignant cells physiological
function could be affected by the process of chelation.
This hypothesis could be extended to include other can-
cerous tumors such as skin cancers amongst others.
Testing the hypothesis
Using the experimental model showing the protective
mechanism of co-cultured reactive astrocytes and tumor
cells treated with oxalates could be used to test this hy-
pothesis in vitro. The calcium specific von Kossa tech-
nique could be used to confirm the presence of chelated
intracellular calcium architecture of the metastatic cells
(which is a sign of apoptosis), and extracellular calcium
chelation stores of the Astrocytes (which has been
shown to slow neural conduction).
Oxalate calcium chelation could inhibit the astrocytes
from sequestering ionic calcium from the cytoplasm of
tumor cells. As per our findings on the oxalate infiltration
and calcium sequestration in atrial myocytes, there should
be a significant attenuation in the reactive astrocyte’s pro-
tective ability for the melanoma tumor cells. Flow mea-
surements in vitro of the cytosolic calcium in oxalate
treated metastatic melanoma cells could support this the-
ory. In vivo experimental approach is the use of iron-clad
nanoparticles with an oxalate payload. Since nanoparticles
are reported to cross the blood–brain barrier [6], calcium
chelators in this case can be selectively deployed by an
outside force, such as magnetism aimed at the tumor area.
Implications of the hypothesis
In malignant melanoma, it has been published that up to
40% of cancer patients will suffer from brain metastasis[7]. The prognosis for these patients is poor, with a life ex-
pectancy of 4 to 6 months [8]. The life expectancy could
be significantly prolonged if the chemotherapeutic issue of
brain metastasis is overcome. Furthermore, just as radi-
ation therapy with the “gamma-knife” technique enables
targeted therapeutic effects not possible with less-targeted
radiation approaches, so too would targeted intracellular
chelation via tailored superparamagnetic ferrous covered
nanoparticles (MNPS) crossing the blood brain barrier
which can be electively guided and deployed by internal
or external force or stimuli [9].
We are not advocating a systemic administration of
calcium chelators, with the consequent deleterious ef-
fects [10], instead a novel use of in situ microinjection
or perhaps a targeted chelation approach delivered Tar-
geted delivery of endogenous substances such as OA
(pH 1.6) and NH4Ox (pH 6.7) should be considered for
inclusion in research protocols of some existing can-
cer treatments.
We conclude that the existing published medical lit-
erature on the extensive correlation of calcium and can-
cer treatment supports and justifies further research
using this novel approach.
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NH4Ox: Ammonium Oxalate; OA: Oxalic Acid.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AE Hypothesis and preliminary calcium chelation work, drafting of
manuscript, final decision. BJS Research chelation design, original chelation
experiments and invaluable support. PJE Substantial contribution, guidance,
drafting and essential focusing of manuscript. MM Pathology Histology
staining and pathologist interpretation. SSP Laboratory Director, funding and
guidance as to selecting Ammonium Oxalate as preferred endogenous
substance. All authors read and approved the final manuscript.
Authors’ information
Abraham Embi- BS- MBA/HA. Associate Consultant, Miami, Florida USA.
Benjamin J Scherlag PH D – Professor of Medicine, University of Oklahoma,
Heart Rhythm Institute, Oklahoma City, Oklahoma, USA. Peter J. Embi MD
FACR Associate Professor of Medicine, Rheumatology. Associate Director
Informatics. The Ohio State University, Columbus, Ohio USA. Manuel Menes
MD Pathology Consultant- Path Opinion, Delray Beach, Florida, USA. Sunny S
Po MD PH D Professor of Medicine, Director Heart Rhythm Institute,
University of Oklahoma, Oklahoma City, Oklahoma, USA.
Author details
1Miami, Florida, USA. 2Health Sciences Center, Heart Rhythm Research
Institute, Department of Medicine, University of Oklahoma, Oklahoma City,
Oklahoma, USA. 3Departments of Biomedical Informatics & Internal Medicine,
The Ohio State University, Columbus, Ohio, USA. 4Pathopinion, Delray Beach,
Florida, USA.
Received: 24 July 2012 Accepted: 30 November 2012
Published: 8 December 2012
Embi et al. Cancer Cell International 2012, 12:51 Page 4 of 4
http://www.cancerci.com/content/12/1/51References
1. Muth JN, Bodi L, Lewis W, Varadi G: A Ca++ dependent transgenic model
of cardiac hypertrophy. Circulation 2001, 103:140.
2. Roderick HL, Cook SJ: Ca2+ signaling checkpoints in cancer: remodeling
Ca2+ for cancer cell proliferation and survival. Nat Rev Cancer 2008,
8:361–375.
3. Lin Q, Balasubramanian K, Fan D, Kim S-J, Guo L, Wang H, Bar-Eli M, Aldape
KD, Fidler IJ: Reactive astrocytes protect melanoma cells from
chemotherapy by sequestering intracellular calcium through Gap
junction communication channels. Neoplasia 2010, 12:748–754.
4. Fan Y, Scherlag B, Embi A, Yu I, Heng C, Mao J, Varma V, Fu G, Po SS:
Neural effects of oxalic acid for atrial fibrillation therapy. 33rd Annu
Sci Session Heart Rhythm 2012, 9:S258.
5. Sheehan DC, Hrapchak BB: Theory and Practice of Histotechnology. 2nd edition.
Columbus, OH: Battelle Memorial Institute; 1987.
6. Bonda DJ, Liu G, Men P, Perry G, Smith MA, Zhu X: Nanoparticle delivery of
transition-metal chelators to the brain: oxidative stress will never see it
coming! CNS Neurol Disord Drug Targets 2012, 11(1):81–85.
7. Soffietti R, Ruda R, Mutani R: Management of brain metastases. J Neurol
2002, 249:1357–1369.
8. McWilliams RR, Rao RD, Brown PD, Link MJ, Buckner JC: Treatment options
for brain metastases from melanoma. Exp Rev Anticancer Ther 2005,
5:809–820.
9. Yu L, Scherlag BJ, Dormer K, Nguyen KT, Pope C, Fung KM, Po SS:
Autonomic denervation with magnetic nanoparticles. Circulation 2010,
122:2653–2659.
10. Mitka M: Chelation Therapy Trials Halted. JAMA 2008, 300(19):2236.
doi:10.1001/jama.2008.607.
doi:10.1186/1475-2867-12-51
Cite this article as: Embi et al.: Targeted cellular ionic calcium chelation
by oxalates: Implications for the treatment of tumor cells. Cancer Cell
International 2012 12:51.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
